Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7961707 | 0.80 | SMN1; SMN2 (0.46) | SMN1; SMN2 | |
| SCHEMBL7960488 | 0.74 | SMN1; SMN2 (0.46) | SMN1; SMN2 | |
| SCHEMBL7951898 | 0.69 | SMN1; SMN2 (0.47) | SMN1; SMN2GAAKMT2ANPSR1ALDH1A1 | |
| SCHEMBL7960325 | 0.69 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL7962014 | 0.69 | SMN1; SMN2 (0.44) | SMN1; SMN2POLBGAAKMT2AALDH1A1 | |
| SCHEMBL7952144 | 0.69 | SMN1; SMN2 (0.44) | SMN1; SMN2GAAKMT2ANPSR1ALDH1A1 | |
| SCHEMBL7952517 | 0.69 | SMN1; SMN2 (0.44) | SMN1; SMN2GAAKDM4E | |
| SCHEMBL5544959 | 0.69 | SMN1; SMN2 (0.65) | SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL9939750 | 0.67 | SMN1; SMN2 (0.57) | SMN1; SMN2 | |
| SCHEMBL29939218 | 0.67 | CA12 (0.57) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | METHYLGENE INC. | 2008-11-13 | — | — | US | disclosed |
| US-6211189-B1 | NITRIC OXIDE SYNTHASE INHIBITORS; ANTIINFLAMMATORY AGENTS, ANALGESICS | ASTRAZENECA UK LIMITED (GB) | 2001-04-03 | — | — | US | disclosed |
| US-6083952-A | Compounds | ASTRA PHARMACEUTICALS LIMITED (GB) | 2000-07-04 | — | — | US | disclosed |
| EP-1000064-A1 | COMPOUNDS | AstraZeneca UK Limited (GB) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999001455-A1 | COMPOUNDS | ASTRA PHARMACEUTICALS LTD. (GB) | 1999-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | CARM1, PRMT1, PRMT3 | SMN1; SMN2 2461/4885CA12 2509/4885CA1 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.